viewBiocept Inc

Biocept to showcase data supporting its CTC liquid biopsy testing platform at 2019 San Antonio Breast Cancer Symposium

The conference is being held from December 10 through the 14th at the Henry B. Gonzalez Convention Center in Austin, Texas

Biocept Inc -
Biocept’s biomarker tests detect and isolate cancer biomarkers

Biocept Inc (NASDAQ:BIOC) has delivered a dose of good news by announcing that clinical data which supports the use of its CTC liquid biopsy testing platform as an instrument to help in the monitoring and treatment of breast cancer will be presented at this year’s San Antonio Breast Cancer Symposium. 

The conference is being held from December 10th through the 14th at the Henry B. Gonzalez convention center in Austin, Texas. 

The San Diego company’s poster presentation is entitled Clinical Data in Over 1,500 Patients Across All Stages of Breast Cancer with Target Selector. 

READ: Biocept unveils latest liquid biopsy test to identify cancer-associated proteins

The hope is that the presentation of a data set, which evaluates over 1,500 patients, will showcase how Biocept’s Target Selector assays aid doctors in their understanding of treatments for breast cancer patients.

“Our CTC-based liquid biopsy testing offers physicians the ability to assess metastatic disease burden and informative biomarkers to aid clinical decision making in patients with breast cancer,” said Dr. Veena Singh, a senior vice-president and a senior medical director at Biocept.

“Additionally, our liquid biopsy testing affords the ability to contemporaneously monitor an evolving tumor mutation landscape in a cost-effective and minimally invasive manner for disease progression, recurrence, emergence of resistance mechanisms, and identification of potentially actionable therapeutic targets,” Dr. Singh said.

Biocept’s biomarker tests detect and isolate cancer biomarkers such as circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA).

Biocept offers the test commercially to doctors, hospitals, clinics and researchers, with a focus on lung, breast, gastric, colorectal and prostate cancers as well as melanoma.

Quick facts: Biocept Inc

Price: 4.41 USD

Market: NASDAQ
Market Cap: $59.07 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...


Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

1 week ago

2 min read